Ga-Pentixafor PET/CT for the Assessment of Therapeutic Outcomes Following Superselective Adrenal Arterial Embolization in Patients with Primary Aldosteronism

Overview

Journal EJNMMI Res

Date 2025 Jan 17

PMID 39821475

Authors

Mengdan Li

Lili Guan

Lu Yang

Wenbo Li

Zhu Xia

Min Mao

Hua Pang

Affiliations

Soon will be listed here.

Abstract

Background: Superselective adrenal artery embolization (SAAE) represents a novel therapeutic strategy for managing primary aldosteronism (PA). Currently, the evaluation of its efficacy is primarily restricted to clinical indicators, with a notable deficiency in imaging evaluation methodologies. In recent years, several studies have investigated the application of Ga-Pentixafor PET/CT for the classification of PA. However, there is a scarcity of specific research investigating the role of PET/CT in the evaluation of efficacy of this condition. Consequently, this study aims to evaluate the therapeutic efficacy of SAAE in patients with PA using Ga-Pentixafor PET/CT, with the objective of establishing imaging evaluation methodologies for assessing PA patients post-SAAE treatment.

Results: Of the 27 patients, 2 achieved complete clinical remission, while 25 experienced partial remission. Biochemically, 13 patients attained complete remission, 13 had partial remission, and 1 did not. For patients with aldosterone-producing adenoma, both visual and semi-quantitative analyses of PET/CT effectively assessed changes in radioactive uptake of the lesion. For idiopathic hyperaldosteronism patients, PET/CT parameters were more effective than visual analysis in evaluating SAAE efficacy. A significant difference in the ΔTLR-40 min parameter was observed across biochemical outcomes (P = 0.041), with patients having ΔTLR-40 min ≥ 0.07 showing better outcomes (AUC = 0.789, P = 0.041).

Conclusions: Ga-Pentixafor PET/CT enables timely assessment of therapeutic outcomes in patients with PA following SAAE, thereby improving clinical decision-making and patient management.

References

Funder J . Primary aldosteronism: Treatment of the disease, and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab. 2019; 34(2):101368. DOI: 10.1016/j.beem.2019.101368. View

Han X, Zhu Q, Li Z, He J, Sun Y, Zhong Q . 4-Hydroxychalcone attenuates AngII-induced cardiac remodeling and dysfunction via regulating PI3K/AKT pathway. Hypertens Res. 2024; 48(3):1054-1067. PMC: 11879844. DOI: 10.1038/s41440-024-02068-w. View

Inoue H, Nakajo M, Miyazono N, Kanetsuki I, Miyake S, Hokotate H . Treatment of aldosteronoma with superselective intraarterial injection of absolute ethanol. Nihon Igaku Hoshasen Gakkai Zasshi. 1994; 54(2):154-62. View

Young Jr W . Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2018; 285(2):126-148. DOI: 10.1111/joim.12831. View

Burton T, Mackenzie I, Balan K, Koo B, Bird N, Soloviev D . Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab. 2011; 97(1):100-9. DOI: 10.1210/jc.2011-1537. View

Dong H, Zou Y, He J, Deng Y, Chen Y, Song L . Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. Catheter Cardiovasc Interv. 2021; 97 Suppl 2:976-981. DOI: 10.1002/ccd.29554. View

Mendichovszky I, Powlson A, Manavaki R, Aigbirhio F, Cheow H, Buscombe J . Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT. Diagnostics (Basel). 2016; 6(4). PMC: 5192517. DOI: 10.3390/diagnostics6040042. View

Lu C, Chen C, Peng K, Chueh J, Chang C, Yen R . Predicting Treatment Response in Primary Aldosteronism Using 11 C-Metomidate Positron Emission Tomography. Clin Nucl Med. 2022; 47(11):936-942. DOI: 10.1097/RLU.0000000000004369. View

Li X, Feng R, Xiang R, Tao L, Zhao Y, Tang P . Bilateral superselective adrenal artery embolization for bilateral primary aldosteronism: a novel approach in an efficacy and safety proof-of-principle trial. Hypertens Res. 2024; 48(1):189-199. DOI: 10.1038/s41440-024-01881-7. View

Hu J, Xu T, Shen H, Song Y, Yang J, Zhang A . Accuracy of Gallium-68 Pentixafor Positron Emission Tomography-Computed Tomography for Subtyping Diagnosis of Primary Aldosteronism. JAMA Netw Open. 2023; 6(2):e2255609. PMC: 9936343. DOI: 10.1001/jamanetworkopen.2022.55609. View

10.

Vaidya A, Hundemer G, Nanba K, Parksook W, Brown J . Primary Aldosteronism: State-of-the-Art Review. Am J Hypertens. 2022; 35(12):967-988. PMC: 9729786. DOI: 10.1093/ajh/hpac079. View

11.

Williams T, Lenders J, Mulatero P, Burrello J, Rottenkolber M, Adolf C . Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017; 5(9):689-699. PMC: 5572673. DOI: 10.1016/S2213-8587(17)30135-3. View

12.

Lim P, Young W, MacDonald T . A review of the medical treatment of primary aldosteronism. J Hypertens. 2001; 19(3):353-61. DOI: 10.1097/00004872-200103000-00001. View

13.

Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y . Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020; 47(11):2656-2665. DOI: 10.1007/s00259-020-04722-0. View

14.

Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F . Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial. J Clin Hypertens (Greenwich). 2020; 22(9):1618-1626. PMC: 8029691. DOI: 10.1111/jch.13960. View

15.

Hokotate H, Inoue H, Baba Y, Tsuchimochi S, Nakajo M . Aldosteronomas: experience with superselective adrenal arterial embolization in 33 cases. Radiology. 2003; 227(2):401-6. DOI: 10.1148/radiol.2272011798. View

16.

Monticone S, DAscenzo F, Moretti C, Williams T, Veglio F, Gaita F . Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2017; 6(1):41-50. DOI: 10.1016/S2213-8587(17)30319-4. View

17.

Heinze B, Fuss C, Mulatero P, Beuschlein F, Reincke M, Mustafa M . Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension. 2017; 71(2):317-325. DOI: 10.1161/HYPERTENSIONAHA.117.09975. View

18.

Inoue H, Nakajo M, Miyazono N, Nishida H, Ueno K, Hokotate H . Transcatheter arterial ablation of aldosteronomas with high-concentration ethanol: preliminary and long-term results. AJR Am J Roentgenol. 1997; 168(5):1241-5. DOI: 10.2214/ajr.168.5.9129420. View

19.

Lindenberg L, Ahlman M, Lin F, Mena E, Choyke P . Advances in PET Imaging of the CXCR4 Receptor: [Ga]Ga-PentixaFor. Semin Nucl Med. 2023; 54(1):163-170. PMC: 10792730. DOI: 10.1053/j.semnuclmed.2023.09.002. View